Teva Plans Phase IIb Trial for TEV-408 Vitiligo Therapy After Phase Ib Success
TEVA•Teva's anti-IL-15 therapy TEV-408 showed favorable safety and preliminary repigmentation signals in a Phase Ib open-label vitiligo study. The company plans a randomized Phase IIb mid-stage trial later this year to confirm efficacy and optimize dosing in an expanded patient cohort.
1. Phase Ib Study Results
The open-label Phase Ib trial evaluated TEV-408 in a small cohort of vitiligo patients over a multi-week period, focusing on safety and initial efficacy. The therapy was well tolerated with no serious adverse events reported and generated preliminary repigmentation signals in affected skin regions. These outcomes supported progression to a larger mid-stage study.
2. Phase IIb Trial Plans
Teva intends to initiate a randomized, placebo-controlled Phase IIb trial in the second half of 2026, expanding patient enrollment across multiple clinical sites. The study will assess repigmentation endpoints and safety over an extended treatment period, aiming to refine optimal dosing levels. Topline data are expected in mid-2027.
3. Strategic Implications
Advancement of TEV-408 underscores Teva’s expansion into immunodermatology beyond its generic portfolio. Successful Phase IIb results could position TEV-408 as a novel vitiligo therapy, challenging existing treatments and potentially creating a new revenue stream in a niche dermatology market.
